Importantly, ICB treatment increased neither H3K9me3, nor DNA-PK, nor γH2AX in RT2.CRISPR-Cdkn2a-cancer cells (Fig. 2c, Supplementary Fig. 3a, b). The gene discussed is CDKN2A; the disease is cancer.